The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of oxaliplatin and S-1 (OS) versus oxaliplatin and capecitabine (XELOX) in patients with advanced or recurrent colorectal cancer.
Dae Young Zang
No relevant relationships to disclose
Ik-Joo Chung
No relevant relationships to disclose
Ho-Suk Oh
No relevant relationships to disclose
Keon Uk Park
No relevant relationships to disclose
Kyung Hee Lee
No relevant relationships to disclose
Boram Han
No relevant relationships to disclose